Skip to main content

Market Overview

Eli Lilly-Vir Bamlanivimab-VIR-7831 Combo Reduces Viral Load By 70% In Low-Risk COVID-19 Patients


Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlanivimab co-administered with VIR-7831 in low-risk adult patients with mild to moderate COVID-19.

  • Results showed that bamlanivimab 700 mg co-administered with VIR-7831 500 mg demonstrated a 70% relative reduction in persistently high viral load at day seven compared to placebo, meeting the primary endpoint.
  • Also, the treatment demonstrated a statistically significant reduction compared to placebo in the critical virologic secondary endpoints of mean change from baseline to days three, five, and seven in SARS-CoV-2 viral load.
  • No events for the secondary endpoint of COVID-19 related hospitalization or death by day 29 in either study arm were reported.
  • One patient (in the treatment arm) visited the emergency room for COVID-19 related symptoms.
  • No serious adverse events were seen with the coadministration of bamlanivimab and VIR-7831.
  • Last week, the FDA acting commissioner Janet Woodcock said that the U.S. government is not distributing Eli Lilly's bamlanivimab alone in California, Arizona, and Nevada amid prevalent COVID-19 virus variants.
  • Price Action: LLY shares are down 0.28% at $184.8, and VIR shares are dow 1.03% at $51 on the last check Monday.

Related Articles (GSK + LLY)

View Comments and Join the Discussion!

Posted-In: COVID-19 CoronavirusBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at